{"disease":{"id":"unresectable-esophageal-cancer","name":"unresectable esophageal cancer"},"drugs":{"marketed":[{"drug_id":"ipilimumab","indication_name":"Unresectable advanced or recurrent esophageal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"capecitabine","indication_name":"Treatment of unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"yervoy","indication_name":"Unresectable advanced or recurrent esophageal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06902545","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","phase":"","overall_status":"RECRUITING","enrollment_count":377,"lead_sponsor_name":"Astellas Pharma Korea, Inc.","has_results":false},{"nct_id":"NCT02625623","title":"Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":371,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT04660760","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06598917","title":"Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT04137679","title":"Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06173986","title":"Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT07039162","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Ming-Yu Lien","has_results":false},{"nct_id":"NCT04005170","title":"Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Mian XI","has_results":false},{"nct_id":"NCT06251973","title":"A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04391049","title":"Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT05400122","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":12,"lead_sponsor_name":"David Wald","has_results":false},{"nct_id":"NCT06048081","title":"Early Access Program for Zolbetuximab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}